Lytgobi TM
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional.
Active ingredients: futabinib
Pack: Lytgobi 4 mg tablet, 35, blister pack
Brand name
(ARTG)
: LYTGOBI futibatinib 4 mg tablet blister packConsumer Medicine Information (CMI)
Read the CMI leaflet for facts you need to know before, during and after taking your medicine.
For more information about CMIs and how to read them, please visit How to read Consumer Medicine Information (CMI).
What this medicine is used for
(ARTG)
LYTGOBI monotherapy has provisional approval in Australia for the treatment of adult patients with locally advanced or metastatic intrahepatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy. The decision to approve this indication has been made on the basis of the favourable objective response rate and duration of response in a single arm trial. Continued approval of this indication depends on verification and description of benefit in confirmatory trials.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Tablet, film coated
- Oral
- LYTGOBI tablets are white, round, film-coated tablets debossed with '4MG' on one side and 'FBN' on the other side.
Storage conditions
(ARTG)
- Store below 25 degrees Celsius
- Shelf lifetime is 48 Months.
Do I need a prescription ?
(ARTG)
These medicine packs are available from a pharmacist and requires a prescription. It is
- 35 tablets pack
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient futabinib
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
